

Avita Medical Ltd. Receives Australian Patent

Patent protects Avita's RESTM technology through 2033 and provides additional claim coverage

Australia, 18 November 2015 — Avita Medical Ltd. (ASX: [AVH](#)), (OTCQX: [AVMXY](#)), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it received a new Australian patent which effectively extends the original ReCell[®] patents to 2033 in Australia and provides greater claim coverage.

Patent No. AU2013202587 relates to use of the Company's cell suspension preparation device, ReCell[®], a simple, rapid and cost-effective technique for grafting cells. As well as lengthening the time frame of the original ReCell[®] patents to 2033 in Australia, the new Australian patent provides additional claim coverage, including conditioned Regenerative Epithelial Suspension[™] (RES[™]) and the methods of preparing and using RES[™] for skin treatment as well as epithelia other than skin, such as cornea and trachea. With the new patent, a broad range of exogenous agents can be added to RES[™], including such items as heat shock protein, hyaluronic acid, and adipose-derived stem cells.

"This patent is an important step in securing the Company's global footprint for our proprietary ReCell[®] technology," said Adam Kelliher, Chief Executive Officer of Avita Medical Ltd. "In addition, it provides further validation of the significant need for our device skin repair technology. We are also excited to now have coverage for several other uses of RES, which we believe creates further value for the Company and our innovative regenerative therapy."

Avita Medical's technology can also be used to treat chronic wounds, burns, scars and a range of skin conditions, including depigmentation and acne.

ABOUT RECELL[®] AND RES[™]

ReCell[®] is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES[™]) using a small sample of the patient's skin. RES[™] is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES[™] has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell[®], is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic

procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION

Avita Medical Ltd

Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
akelliher@avitamedical.com

Avita Medical Ltd

Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
trooney@avitamedical.com

Avita Medical Ltd

Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
gabriel@laurus.net.au

UK/EU**Instinctif Partners**

Gemma Howe/Sue Charles
Phone +44 (0)20 7866 7860
avitamedical@instinctif.com

USA**The Ruth Group**

Lee Roth, Investor Relations
Kirsten Thomas, Public
Relations
Phone: +1 (646) 536-7012 / +1
(508) 280-6592
lroth@theruthgroup.com
/ kthomas@theruthgroup.com

Australia**Monsoon Communications**

Rudi Michelson
Investor Relations / PR
Phone: +61 3 9620 3333
rudim@monsoon.com.au